Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.

[1]  R. Dummer,et al.  Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. , 2020, European journal of cancer.

[2]  C. Elmets,et al.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.

[3]  S. Whittaker,et al.  ‘We had to change to single beds because I itch in the night’: a qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T‐cell lymphoma , 2015, The British journal of dermatology.

[4]  M. Weinstock,et al.  Changing incidence trends of cutaneous T-cell lymphoma. , 2013, JAMA dermatology.

[5]  E. Linos,et al.  Development of a Quality of Life Instrument Specific for Cutaneous Lymphoma , 2011 .

[6]  J. Becker,et al.  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Misery,et al.  Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat. , 2010, Acta dermato-venereologica.

[8]  S. Bates,et al.  Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Wilson,et al.  Patient Perspectives Regarding the Value of Total Skin Electron Beam Therapy for Cutaneous T-Cell Lymphoma/Mycosis Fungoides: A Pilot Study , 2009, American journal of clinical oncology.

[10]  S. Horwitz,et al.  Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  T. Kuzel,et al.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Gan,et al.  Significant impact of cutaneous T‐cell lymphoma on patients' quality of life , 2006, Cancer.

[13]  Donald R. Miller,et al.  Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma. , 2005, Archives of dermatology.

[14]  P. Heald,et al.  Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. , 2003, Journal of the American Academy of Dermatology.

[15]  A. Varghese,et al.  Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. , 2003, Archives of dermatology.

[16]  T. Kuzel,et al.  Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). , 2002, Clinical lymphoma.

[17]  M. Duvic,et al.  Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Bisaccia,et al.  Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution. , 2000, Journal of the American Academy of Dermatology.

[19]  W M Tierney,et al.  Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. , 1999, Medical care.

[20]  M. Chren,et al.  Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. , 1997, Archives of dermatology.

[21]  Mark S. Litwin,et al.  How to Measure Survey Reliability and Validity , 1995 .

[22]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.